$LENZ
LENZ Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024021135 Filed on February 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.551M $14.60M $40.97M
YoY Change -27.18% 76.15% 24.72%
% of Gross Profit
Research & Development $10.54M $1.000K $32.14M
YoY Change -35.13% -99.99% -55.85%
% of Gross Profit
Depreciation & Amortization $5.000K $142.0K $2.400M
YoY Change -99.29% -79.18% 2.04%
% of Gross Profit
Operating Expenses $16.09M $14.60M $135.2M
YoY Change -39.18% -45.42% 27.97%
Operating Profit -$16.09M -$135.2M
YoY Change -39.18% 27.97%
Interest Expense $788.0K $2.562M $10.95M
YoY Change -69.58%
% of Operating Profit
Other Income/Expense, Net -$560.0K $75.00K $10.54M
YoY Change -122.26% -96.51% 129.78%
Pretax Income -$16.65M -$22.92M -$124.7M
YoY Change -30.44% -6.83% 23.35%
Income Tax
% Of Pretax Income
Net Earnings -$16.65M -$22.92M -$124.7M
YoY Change -30.44% -6.83% 23.29%
Net Earnings / Revenue
Basic Earnings Per Share -$3.53 -$2.19
Diluted Earnings Per Share -$3.53 -$0.40 -$2.19
COMMON SHARES
Basic Shares Outstanding 58.24M 58.00M 57.02M
Diluted Shares Outstanding 4.718M shares 57.02M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $213.3M $184.3M $184.3M
YoY Change -19.24% -31.31% -31.31%
Cash & Equivalents $200.4M $184.3M $184.3M
Short-Term Investments $12.92M $0.00 $0.00
Other Short-Term Assets $3.395M $3.762M $3.762M
YoY Change -45.34% -47.28% -47.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $216.7M $188.0M $188.0M
YoY Change -19.84% -31.72% -31.72%
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K $0.00 $321.0K
YoY Change -99.85% -100.0% -98.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $21.00K $0.00 $114.0K
YoY Change -97.64% -100.0% -96.21%
Total Long-Term Assets $648.0K $435.0K $435.0K
YoY Change -98.37% -99.07% -99.07%
TOTAL ASSETS
Total Short-Term Assets $216.7M $188.0M $188.0M
Total Long-Term Assets $648.0K $435.0K $435.0K
Total Assets $217.3M $188.5M $188.5M
YoY Change -29.9% -41.46% -41.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.131M $250.0K $250.0K
YoY Change 257.98% -90.41% -90.41%
Accrued Expenses $11.76M $4.547M $4.547M
YoY Change -4.79% -56.43% -56.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.89M $4.797M $4.797M
YoY Change 31.71% -63.22% -63.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $111.0K $0.00 $77.00K
YoY Change -99.43% -100.0% -99.39%
Total Long-Term Liabilities $111.0K $0.00 $77.00K
YoY Change -99.43% -100.0% -99.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.89M $4.797M $4.797M
Total Long-Term Liabilities $111.0K $0.00 $77.00K
Total Liabilities $19.16M $4.874M $4.874M
YoY Change -43.28% -80.97% -80.97%
SHAREHOLDERS EQUITY
Retained Earnings -$111.9M -$367.1M
YoY Change -57.98% 51.44%
Common Stock $0.00 $1.000K
YoY Change -100.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.2M $183.6M $183.6M
YoY Change
Total Liabilities & Shareholders Equity $217.3M $188.5M $188.5M
YoY Change -29.9% -41.46% -41.46%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$16.65M -$22.92M -$124.7M
YoY Change -30.44% -6.83% 23.29%
Depreciation, Depletion And Amortization $5.000K $142.0K $2.400M
YoY Change -99.29% -79.18% 2.04%
Cash From Operating Activities -$23.94M -$45.88M -$90.01M
YoY Change 13.59% 104.54% 2.28%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $50.00K $10.86M
YoY Change -100.0% -95.1% 64.63%
Acquisitions
YoY Change
Other Investing Activities $18.00M $47.13M $237.2M
YoY Change -58.66% 224.04% -200.82%
Cash From Investing Activities $18.00M $47.08M $226.3M
YoY Change -58.3% 248.14% -193.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $171.3M 66.00K 190.0K
YoY Change -2140950.0% -72.95% -68.17%
NET CHANGE
Cash From Operating Activities -$23.94M -45.88M -90.01M
Cash From Investing Activities $18.00M 47.08M 226.3M
Cash From Financing Activities $171.3M 66.00K 190.0K
Net Change In Cash $165.3M 1.271M 136.5M
YoY Change 648.75% -114.67% -141.47%
FREE CASH FLOW
Cash From Operating Activities -$23.94M -$45.88M -$90.01M
Capital Expenditures $0.00 $50.00K $10.86M
Free Cash Flow -$23.94M -$45.93M -$100.9M
YoY Change 11.56% 95.85% 6.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001815776
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2020Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 grph Operating Lease Commencement Date
OperatingLeaseCommencementDate
2021-07-31
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 grph Other Income Expense
OtherIncomeExpense
CY2023 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherAssetImpairmentCharges
CY2022 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherAssetImpairmentCharges
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40532
CY2023 dei Entity Registrant Name
EntityRegistrantName
GRAPHITE BIO, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4867570
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Blvd
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
484-0886
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2023 dei Trading Symbol
TradingSymbol
GRPH
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
150800000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58236926
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184259000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
220499000
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1602000
CY2022Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2160000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
188021000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
275365000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
114000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1716000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
15322000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
321000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5580000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1289000
CY2023Q4 us-gaap Assets
Assets
188456000
CY2022Q4 us-gaap Assets
Assets
321902000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
250000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2608000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1534000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3799000
CY2023Q4 grph Accrued Research Costs
AccruedResearchCosts
0
CY2022Q4 grph Accrued Research Costs
AccruedResearchCosts
720000
CY2023Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2728000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2023 us-gaap Operating Expenses
OperatingExpenses
135191000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
285000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4045000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4797000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13043000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1749000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10819000
CY2023Q4 us-gaap Liabilities
Liabilities
4874000
CY2022Q4 us-gaap Liabilities
Liabilities
25611000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58008396
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58008396
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58221760
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58221760
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
550635000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
539741000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1048000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367054000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242403000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
183582000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
188456000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321902000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32137000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72787000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40973000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32852000
CY2023 us-gaap Restructuring Costs
RestructuringCosts
62081000
CY2022 us-gaap Restructuring Costs
RestructuringCosts
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
105639000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-135191000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-105639000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10949000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4587000
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-71000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2023 grph Other Income Expense
OtherIncomeExpense
-338000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10540000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4587000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124651000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1048000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1048000
CY2023 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-123603000
CY2022 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-102100000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57015159
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57015159
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54873675
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54873675
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384050000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
656000
CY2022 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
131000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13534000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1048000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
157000
CY2023 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
63000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10574000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1048000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124651000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
183582000
CY2023 us-gaap Profit Loss
ProfitLoss
-124651000
CY2022 us-gaap Profit Loss
ProfitLoss
-101052000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1543000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1600000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2407000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2352000
CY2023 grph Non Cash Lease Expense
NonCashLeaseExpense
4289000
CY2022 grph Non Cash Lease Expense
NonCashLeaseExpense
5994000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
10574000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
13534000
CY2023 grph Gain On Asset Abandonment
GainOnAssetAbandonment
-1638000
CY2022 grph Gain On Asset Abandonment
GainOnAssetAbandonment
0
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-71000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
56621000
CY2022 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5676000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3211000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2358000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2265000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1110000
CY2023 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
-720000
CY2022 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
87000
CY2023 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
1806000
CY2022 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
94000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-41362000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5482000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90007000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87980000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10856000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6594000
CY2023 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
1904000
CY2022 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28129000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
405519000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
263427000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
170250000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
226346000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-241863000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
157000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
656000
CY2023 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
67000
CY2022 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
79000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
190000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
597000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
136529000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-329246000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
378692000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
185975000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184259000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
185975000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2023 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
0
CY2022 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
-36000
CY2023 grph Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
7193000
CY2022 grph Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
11920000
CY2023 grph Additions To Right Of Use Assets From New Operating Lease Liabilities
AdditionsToRightOfUseAssetsFromNewOperatingLeaseLiabilities
31974000
CY2022 grph Additions To Right Of Use Assets From New Operating Lease Liabilities
AdditionsToRightOfUseAssetsFromNewOperatingLeaseLiabilities
0
CY2023 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
63000
CY2022 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
131000
CY2023 grph Repurchase Of Unvested Early Exercised Shares Included In Accounts Payable
RepurchaseOfUnvestedEarlyExercisedSharesIncludedInAccountsPayable
0
CY2022 grph Repurchase Of Unvested Early Exercised Shares Included In Accounts Payable
RepurchaseOfUnvestedEarlyExercisedSharesIncludedInAccountsPayable
17000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367100000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
184300000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the marketable securities, stock-based compensation expense, accruals for research and development costs, lease assets and liabilities, the valuation of deferred tax assets, uncertain income tax positions, and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with major financial institution and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institution in which the cash and cash equivalents are held. The Company has not experienced any losses on deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1600000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
54100000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 grph Research And Development Credits To Offset Payroll Tax Expenses
ResearchAndDevelopmentCreditsToOffsetPayrollTaxExpenses
300000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
236869000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1076000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
235821000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Supplies
Supplies
0
CY2022Q4 us-gaap Supplies
Supplies
2486000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
780000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1343000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1380000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3307000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2160000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25837000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3207000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2023 us-gaap Depreciation
Depreciation
2400000
CY2022 us-gaap Depreciation
Depreciation
2400000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1029000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000
CY2023Q4 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
21000
CY2022Q4 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
150000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
143000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1354000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1535000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
0
CY2023Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2728000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2024 grph Percentage Of Equity Interest On Outstanding Shares
PercentageOfEquityInterestOnOutstandingShares
0.20
CY2023 grph Amount Of Equity Interest On Outstanding Shares
AmountOfEquityInterestOnOutstandingShares
0
CY2023Q4 grph Accrued Termination And Cancellation Charges
AccruedTerminationAndCancellationCharges
0
CY2022Q4 grph Accrued Termination And Cancellation Charges
AccruedTerminationAndCancellationCharges
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P15M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P19M
CY2023Q4 grph Lessee Operating Lease Weighted Average Incremental Borrowing Rate
LesseeOperatingLeaseWeightedAverageIncrementalBorrowingRate
0.09
CY2022Q4 grph Lessee Operating Lease Weighted Average Incremental Borrowing Rate
LesseeOperatingLeaseWeightedAverageIncrementalBorrowingRate
0.085
CY2023Q4 grph Prepayments Lease Amendment
PrepaymentsLeaseAmendment
15900000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
304000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
78000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
382000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
362000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
7300000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6700000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
2200000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1300000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
44123000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17428919
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13893161
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The shares of the Company’s common stock issued to its founders for their services as an employee, advisor, or consultant vest monthly over four years with one year cliff from the vesting commencement date.
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023 grph Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
CY2020Q2 grph Aggregate Common Stock Vested
AggregateCommonStockVested
912212
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7273848
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
564000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
564000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.56
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2023 grph Early Exercise Of Stock Options Repurchase Right Lapse Period
EarlyExerciseOfStockOptionsRepurchaseRightLapsePeriod
P180D
CY2023 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
227792
CY2022 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
189414
CY2023Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
68868
CY2022Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
554695
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10574000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13534000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10574000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13534000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-124651000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
58046553
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
58111437
CY2023 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
1031394
CY2022 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
3237762
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57015159
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57015159
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54873675
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54873675
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5942040
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10690909
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0101
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0069
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0111
CY2023 grph Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
-0.0101
CY2022 grph Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0
CY2023 grph Effective Income Tax Rate Reconciliation Lease Modification
EffectiveIncomeTaxRateReconciliationLeaseModification
0.0327
CY2022 grph Effective Income Tax Rate Reconciliation Lease Modification
EffectiveIncomeTaxRateReconciliationLeaseModification
0
CY2023 grph Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0
CY2022 grph Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0152
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0097
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2369
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2155
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30820000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15940000
CY2023Q4 grph Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development Costs
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopmentCosts
14493000
CY2022Q4 grph Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development Costs
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopmentCosts
13815000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
7201000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
5699000
CY2023Q4 grph Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
88000
CY2022Q4 grph Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
1220000
CY2023Q4 grph Gain Loss On Termination Of Lease Cost
GainLossOnTerminationOfLeaseCost
6621
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2017000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1703000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
295000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
735000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
6161000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
170000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
67699000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39285000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67626000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38110000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
73
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1175
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
73000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1175000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
73000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1175000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38110000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16332000
CY2023 grph Valuation Allowance Increases Recorded To Income Tax Provision
ValuationAllowanceIncreasesRecordedToIncomeTaxProvision
29516000
CY2022 grph Valuation Allowance Increases Recorded To Income Tax Provision
ValuationAllowanceIncreasesRecordedToIncomeTaxProvision
21778000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67626000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38110000
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company’s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years from inception through December 31, 2022. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2701000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1407000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
899000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1862000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
42000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
568000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3558000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2701000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Defined Benefit Plan Special Termination Benefits
DefinedBenefitPlanSpecialTerminationBenefits
1000000
CY2023 grph Defined Benefit Plan Special Termination Benefits Paid
DefinedBenefitPlanSpecialTerminationBenefitsPaid
600000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
0
CY2023 grph Severance Costs Incurred
SeveranceCostsIncurred
8100000
CY2023 us-gaap Severance Costs1
SeveranceCosts1
-6565000
CY2023Q4 grph Accrued Employee Termination Benefits Ending Balance
AccruedEmployeeTerminationBenefitsEndingBalance
1535000
CY2023 grph Employees Retention Bonus Payable
EmployeesRetentionBonusPayable
4200000
CY2023 grph Employees Retention Bonus Amount
EmployeesRetentionBonusAmount
3700000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
46900000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 grph Rule10 B51 Arrangement Modified Flag
Rule10B51ArrangementModifiedFlag
false
CY2023Q4 grph Non Rule10 B51 Arrangement Modified Flag
NonRule10B51ArrangementModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2023 dei Auditor Firm
AuditorFirmId
34

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-021135-index-headers.html Edgar Link pending
0000950170-24-021135-index.html Edgar Link pending
0000950170-24-021135.txt Edgar Link pending
0000950170-24-021135-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grph-20231231.htm Edgar Link pending
grph-20231231.xsd Edgar Link pending
grph-ex10_27.htm Edgar Link pending
grph-ex21_1.htm Edgar Link pending
grph-ex23_1.htm Edgar Link pending
grph-ex31_1.htm Edgar Link pending
grph-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
grph-20231231_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending